Manu et al. showed that the therapeutic effect of isorhamnetin combined with capecitabine was superior to capecitabine alone, and could significantly inhibit the viability of tumor cells, the expression of tumor markers, inhibit the activation of the NF-κB signaling pathway, and enhance the antitumor effects of capecitabine [84]. This evidence concerns the gene NFKB1 and neoplasm.